Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. He served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (“Roche”), during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company.
Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine, and Memorial Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the Boards of Directors of Black Diamond Therapeutics, Inc., Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and he has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, and Exosome Diagnostics. He is a member of the NCI Experimental Therapeutics Panel. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Dr. Dhingra obtained his M.B.B.S. degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine.
Steve Hurly brings nearly two decades of leadership experience in the life sciences industry. He served as President and Chief Executive Officer of Sesen Bio, a NASDAQ listed late stage oncology firm. Prior he served as the President and Chief Executive Officer of Viventia Bio Inc., a specialty pharmaceutical company acquired by Sesen Bio Inc in September 2016. Steve has more than 15 years of experience in the investment banking business. He has served on the board of directors of PHusis Therapeutics Inc., a private targeted small molecule therapeutics company, since May 2011. Previously, he was the Chief Executive Officer of Burrill & Co.’s Merchant Banking Division, a finance business for life science companies. He was also the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm. He graduated from Swarthmore College with a B.A. degree in Engineering and earned an M.B.A. from the University of Chicago.
Nanna joined Novo Holdings in 2012, and spent four years in Novo Seeds, where she helped build a strong portfolio of seed and Series A stage companies. She led the initial investments and served on the Boards as Director or Observer at Inthera, IO Biotech, MinervaX, Pcovery, Forendo and Galecto. Nanna joined Novo Ventures in 2016 and has been involved in both private and public investments, including successful public listings of Orphazyme (ORPHA), ObsEva (OBSV), and Inventiva (IVA). She currently serves on the boards of NodThera, ReViral, Stargazer and Lava.
Prior to her time at Novo Holdings, Nanna was part of the life science investment team at Apposite Capital, a London-based venture fund, where she participated in both primary and secondary investments, with multiple deals leading to highly successful exits for the fund, including Convergence, Ulthera and Cancer Partners UK. She has previously worked at Cancer Research UK as a research analyst, and as a consultant to various biotech and healthcare venture projects during her MBA. Nanna received her PhD in Neuroscience from University College London, an MBA with distinction from University of Cambridge, and a 1st class BA from University of Oxford.
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V., Amphista Therapeutics Ltd. and Lumicks B.V. Prior to joining Gilde, Stefan worked at Merck KGaA where he completed international assignments in the Global Business Intelligence and M Ventures divisions. Stefan received a B.Sc. in Biology and M.Sc. in Biotechnology from the Swiss Federal Institute of Technology Zurich (ETH) and his MPhil in Bioscience Enterprise from the University of Cambridge. He completed his Ph.D. with Nobel Laureate Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge, where he developed a bicyclic peptide-based drug discovery platform.
Guido Magni, M.D., Ph.D., is a Partner with Versant Ventures. He brings deep experience in drug development from multiple accomplishments at leading global pharmaceutical companies including Roche and Wyeth. Guido held the position of Global Head of the Medical Science Department at Roche for 12 years and built a track record that includes the approval of 15 new drugs across various therapeutic areas during this time, including blockbuster products Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Guido brings this critical expertise to Versant portfolio companies by providing guidance on their clinical and regulatory strategies.
Joël is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology in 2001 and was its CEO until it was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva®, the first breakthrough designated drug approved by the FDA for B-CLL. He holds an MS in Biotechnology and a PhD from the Swiss Federal Institute of Technology (ETH) in Zurich. Joël is currently on the boards of directors of Adcendo, Sanifit Therapeutics, Ona Therapeutics, SpliceBio, Executive Chairman of Inbiomotion, and board observer at AM-Pharma. He has been Chairman of the board of Cellerix/Tigenix (now Takeda), board member of Aura Biosciences and board observer at Biovex (now Amgen). Joël has earned numerous awards, including the Wall Street Journal’s Europe Innovation Award in 2001.
Erik has over twenty years of experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several (bio)tech companies. Previously, as a senior executive at Organon (currently Merck) he was responsible for leading the Company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600M option to acquire AM-Pharma by Pfizer and raised more than €130M in equity and debt financing. He concluded his Masters in chemistry from the University of Utrecht and an MBA from Manchester Business School both with honors.
Karen Wilson has served as one of our supervisory directors since March 2021. She currently serves on the board of directors of Angion Biomedica, Connect Biopharma, and Vaxart, Inc. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.